PUBLISHER: Meticulous Research | PRODUCT CODE: 2178442
PUBLISHER: Meticulous Research | PRODUCT CODE: 2178442
The global veterinary molecular diagnostics market was valued at USD 812.6 million in 2025. The market is estimated at USD 886.4 million in 2026 and is projected to reach USD 2,135.8 million by 2036, at a CAGR of 9.2% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering animal disease trends, PCR, sequencing, microarray, and point-of-care technologies, molecular versus immunoassay testing, regulation, cost per test, the supplier landscape, and future growth opportunities.
The market covers the kits, reagents, instruments, and software that laboratories and clinics use to read pathogen and animal DNA and RNA for disease diagnosis, surveillance, and genetic testing. Products in scope include PCR assays in real-time, digital, and conventional formats, multiplex syndromic panels, extraction kits and automated extraction systems, thermal cyclers and point-of-care molecular analyzers, sequencing for pathogen characterization and genotyping, genotyping microarrays, and laboratory and data analysis software. ELISA and other immunoassays, rapid antigen and antibody tests, clinical chemistry, hematology, imaging, food safety testing of animal products, environmental DNA monitoring of wildlife, and human molecular diagnostics are excluded.
Between January 2022 and June 2026, African swine fever (ASF) was reported by 76 countries and territories, according to the World Organisation for Animal Health (WOAH), with 14,951 outbreaks in domestic pigs, 2.74 million animals lost, and 34,388 outbreaks in wild boar, and Finland recorded its first case in wild boar in July 2026. In the U.K., Defra had confirmed 270 bluetongue virus serotype 3 (BTV-3) cases on farms in England and Wales by August 7, 2026, within a month of the season's first case on July 10, after 348 cases in Great Britain in 2025-2026. On the companion animal side, IDEXX Laboratories reported second-quarter 2026 revenue of USD 1,217 million, up 10%, with Companion Animal Group Diagnostics recurring revenue up 11%.
Market Dynamics
Outbreaks of transboundary and zoonotic diseases are a major driver of the veterinary molecular diagnostics market, because governments and producers rely on sensitive PCR testing to confirm cases, set restriction zones, and clear animals for movement and trade. With no widely available ASF vaccine in most countries, control depends on early detection and culling, and disease-free countries keep testing to catch any introduction. H5N1 avian influenza has reached U.S. dairy cattle since 2024, and the USDA Animal and Plant Health Inspection Service (APHIS) continues the National Milk Testing Strategy alongside an April 2024 Federal Order requiring tests of lactating dairy cattle before interstate movement. Rising pet ownership and spending on care, broader reference laboratory PCR panels for respiratory, gastrointestinal, and vector-borne disease in dogs and cats, and genomic selection, parentage, and trait testing in cattle, swine, and poultry add further demand.
Molecular tests cost more than rapid antigen and antibody tests and need specialized instruments and staff, so low-margin livestock producers often test only in outbreaks or for high-value animals. Many countries in Africa, Asia, and Latin America lack veterinary laboratory capacity outside major cities. Assays for notifiable diseases often need national approval or validation, which adds time and cost despite WOAH harmonization, a positive PCR result does not always mean active infection, and livestock testing volumes rise sharply in outbreaks and fall afterward, which complicates capacity and inventory planning.
Point-of-care PCR and isothermal systems that give results during the clinic visit or pen-side on farms are a key opportunity, as is whole-genome sequencing for strain identification, outbreak tracing, new variants, and antimicrobial resistance genes, as seen in sequencing of H5N1 viruses from cattle and poultry. One Health surveillance programs and new veterinary laboratories in China, India, Brazil, and Southeast Asia offer further openings. Key trends include multiplex syndromic panels, consolidation of diagnostics and genetics, and closer links between testing, practice management software, and surveillance platforms.
Segment Analysis
The report analyzes the market by product, technology, application, animal type, end user, and geography, helping stakeholders identify the most attractive growth areas.
By product, the veterinary molecular diagnostics market is segmented into kits & reagents, instruments, and software. Kits & reagents span assay, extraction, and sequencing kits and other reagents, and instruments span PCR, sequencing, and extraction systems and point-of-care analyzers. Kits & reagents are expected to hold the largest share in 2026, since PCR kits and extraction reagents are used up in every test, surveillance of ASF, avian influenza, and bluetongue requires very large test volumes, and companion animal reference laboratory panels keep expanding. Software is projected to record the highest CAGR, as testing is linked with laboratory information systems, practice management tools, and surveillance platforms and sequencing output needs bioinformatics analysis. Instruments should grow steadily on laboratory automation and point-of-care analyzers.
By technology, the veterinary molecular diagnostics market is segmented into PCR, DNA sequencing, microarray, and other technologies such as LAMP and other isothermal methods. PCR, covering real-time, digital, and conventional PCR, leads in 2026, as real-time PCR is the standard method for confirming viral and bacterial pathogens, WOAH diagnostic standards recommend it for many notifiable diseases, and it underpins national ASF, avian influenza, and bluetongue programs and companion animal panels. DNA sequencing, including next-generation and Sanger sequencing, is set to grow the fastest, supported by lower sequencing costs, wider use of whole-genome sequencing for pathogen typing, outbreak tracing, and resistance detection, and sequencing-based genotyping in animal genetics. Microarrays stay relevant for livestock genotyping.
By application, the veterinary molecular diagnostics market is segmented into infectious diseases (viral, bacterial, parasitic, and fungal), genetics (inherited disease, genomic selection & trait, and parentage & identity testing), metabolic diseases, and other applications such as oncology and pharmacogenetics. Infectious diseases hold the largest share in 2026, reflecting the central role of PCR in diagnosing and monitoring infections in livestock and pets, the impact of ASF, avian influenza, and bluetongue, and the routine use of infectious disease panels in clinics. Genetics is projected to record the highest CAGR, driven by genomic selection by cattle, pig, and poultry breeders, DNA tests for inherited diseases and traits in dogs and cats, and animal health company investment in genomics, including Zoetis' agreement to acquire Neogen's genomics business.
By animal type, the veterinary molecular diagnostics market is segmented into companion animals (dogs, cats, horses, and other companion animals) and livestock animals (cattle, swine, poultry, small ruminants, and other livestock animals). Companion animals are expected to hold the largest share in 2026, supported by high spending on pet care, routine ordering of PCR panels for dogs and cats from reference laboratories, and strong growth in companion animal diagnostics, as IDEXX's results show. Livestock animals are projected to grow the fastest, as ASF, avian influenza, and bluetongue spread, national surveillance and pre-movement testing programs expand, and breeders adopt genomic testing. Cattle are expected to be a major part of livestock demand, given H5N1 testing in dairy herds, bluetongue surveillance, and genomic selection.
By end user, the veterinary molecular diagnostics market is segmented into veterinary reference & diagnostic laboratories, veterinary hospitals & clinics, and research institutes. Reference & diagnostic laboratories, including commercial reference laboratories and national, state, and university laboratories, hold the largest share in 2026, as molecular testing is concentrated where the instruments and expertise exist, IDEXX and Antech Diagnostics run large reference networks, and government laboratories test for notifiable diseases. Veterinary hospitals & clinics are set to grow the fastest, supported by point-of-care molecular analyzers, veterinarians' wish for results during the visit, and large hospital groups building in-house diagnostics.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 20 countries and four rest-of-region groups. The regional analysis considers livestock populations, disease outbreaks, pet care spending, laboratory networks, and surveillance programs.
North America is expected to hold the largest share of the global veterinary molecular diagnostics market in 2026, supported by high companion animal healthcare spending, the reference laboratory networks of IDEXX and Antech Diagnostics, home-based suppliers including Zoetis, Neogen, and Thermo Fisher Scientific, and broad livestock disease surveillance, including H5N1 milk and pre-movement testing. The U.S. is also the biggest single market for genomic testing of livestock.
Asia-Pacific is projected to grow at the highest CAGR, driven by large pig and poultry populations, ASF and avian influenza in China, Vietnam, and other countries, new veterinary diagnostic laboratories, and fast-rising pet ownership and care spending in China, Japan, South Korea, and India. China, the world's largest pig producer, is seeing strong PCR demand from ASF control and the growth of large commercial farms. Europe holds a significant share, supported by ASF in wild boar and domestic pigs, bluetongue and avian influenza outbreaks, strong national laboratory systems, and specialist suppliers based in the region, including Germany's Indical Bioscience and France's Innovative Diagnostics. Latin America, led by the large livestock industries of Brazil, Argentina, and Mexico, and the Middle East & Africa, supported by investment in veterinary services and disease control, account for smaller shares.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025. Company profiles include business and financial overviews, veterinary molecular diagnostics portfolios, product portfolios, strategic developments, and SWOT analyses.
Animal health and diagnostics leaders such as IDEXX, Antech Diagnostics, and Zoetis compete in the moderately consolidated veterinary molecular diagnostics market alongside life science suppliers including QIAGEN, Bio-Rad Laboratories, and Thermo Fisher Scientific and specialists such as Indical Bioscience, Innovative Diagnostics, and Neogen. Competition rests on assay menu breadth, approvals and validations, sensitivity and specificity, throughput and automation, turnaround time, point-of-care capability, and ties with reference laboratories and national veterinary authorities. Leading players are widening assay menus, building multiplex panels and point-of-care platforms, investing in automation and sequencing, and connecting testing with software. Notable developments include Neogen's March 2026 agreement to sell its GeneSeek genomics business, including the Igenity and GGP portfolios, to Zoetis, Mars' combination of Heska with Antech Diagnostics, and continued growth in IDEXX reference laboratory revenue.
Key companies profiled in the report include IDEXX Laboratories, Inc. (U.S.), Antech Diagnostics, Inc. (Mars, Incorporated) (U.S.), Zoetis Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Neogen Corporation (U.S.), Indical Bioscience GmbH (Germany), and Innovative Diagnostics SAS (France).
How This Report Helps
Key Questions Answered